#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15122	16S	1529	1529	99.93	16S.l15.c4.ctg.2	2589	719.2	0	.	n	.	0	C1450T	SNP	1450	1450	C	1925	1925	T	970	T,A	968,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15122	16S	1529	1529	99.93	16S.l15.c4.ctg.2	2589	719.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1659	1659	C	947	C,T,A	945,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26250	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4162	786.1	0	.	n	.	0	C543T	SNP	543	543	C	1146	1146	T	941	T,A,C,G	937,1,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26250	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4162	786.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1940	1940	A	1053	A	1052	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26250	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4162	786.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2574	2574	C	994	C,A	993,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26250	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4162	786.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2648	2648	A	935	A	935	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26250	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4162	786.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	3200	3200	C	937	C,A,T,G	934,1,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	2170	folP	855	855	99.88	folP.l15.c4.ctg.1	2074	130.7	1	SNP	p	R229S	1	.	.	685	687	AGC	1340	1342	AGC	231;232;233	A;G;C	231;232;233	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5398	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3790	177.3	0	.	p	.	0	V290I	NONSYN	868	870	GTT	1340	1342	ATT	218;216;214	A,G;T;T,G	217,1;216;213,1	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5398	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3790	177.3	1	SNP	p	S91F	0	.	.	271	273	TCC	743	745	TCC	199;196;196	T;C;C	199;196;196	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5398	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3790	177.3	1	SNP	p	D95G	0	.	.	283	285	GAC	755	757	GAC	204;205;205	G;A;C	204;205;205	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5398	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3790	177.3	1	SNP	p	D95N	0	.	.	283	285	GAC	755	757	GAC	204;205;205	G;A;C	204;205;205	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_L_00489c	mtrR.WHO_L_00489c	1	1	27	1962	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1741	140.2	1	SNP	p	G45D	1	.	.	133	135	GAC	696	698	GAC	232;231;233	G;A,G;C	232;230,1;233	mtrR.WHO_L_00489c:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1212	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c17.ctg.1	1536	98.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4830	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3377	178.2	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1831	1833	GCA	254;255;255	G;C;A,T	254;255;254,1	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4830	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3377	178.2	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2314	2316	ATT	228;227;226	A;T;T,A	228;227;225,1	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4830	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3377	178.2	1	SNP	p	D86N	0	.	.	256	258	GAC	784	786	GAC	213;217;218	G;A,G,C;C	213;215,1,1;218	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4830	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3377	178.2	1	SNP	p	S87I	0	.	.	259	261	AGT	787	789	AGT	216;218;216	A,T;G;T,C	215,1;218;215,1	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4830	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3377	178.2	1	SNP	p	S87R	0	.	.	259	261	AGT	787	789	AGT	216;218;216	A,T;G;T,C	215,1;218;215,1	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4830	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3377	178.2	1	SNP	p	S87W	0	.	.	259	261	AGT	787	789	AGT	216;218;216	A,T;G;T,C	215,1;218;215,1	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4830	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3377	178.2	1	SNP	p	S88P	0	.	.	262	264	TCC	790	792	TCC	217;217;217	T;C;C	217;217;217	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4486	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3236	172.6	0	.	p	.	0	H611N	NONSYN	1831	1833	CAC	2493	2495	AAC	226;226;225	A,C;A,C;C	225,1;225,1;223	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4486	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3236	172.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1890	1892	GGC	223;224;225	G,C;G;C	222,1;224;225	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	4380	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2853	191.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1562	1564	GCA	264;264;263	G;C,G,A;A	264;262,1,1;263	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4380	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2853	191.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1565	1567	ATC	264;263;265	A;T,G;C	264;262,1;265	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4380	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2853	191.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1577	1579	GTG	264;265;268	G;T;G	264;265;268	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4380	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2853	191.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1577	1579	GTG	264;265;268	G;T;G	264;265;268	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4380	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2853	191.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2081	2083	ACC	251;251;247	A,G;C;C	250,1;251;247	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4380	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2853	191.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2135	2137	GCG	227;227;227	G;C,G;G	227;226,1;227	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4380	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2853	191.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2135	2137	GCG	227;227;227	G;C,G;G	227;226,1;227	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4380	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2853	191.2	1	SNP	p	G543S	0	.	.	1627	1629	GGT	2258	2260	GGT	249;249;251	G,A,T;G;T,C	247,1,1;249;250,1	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4380	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2853	191.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2267	2269	GGC	252;254;255	G;G,T;C	252;253,1;255	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4380	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2853	191.2	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2285	2287	CCG	245;246;242	C;C;G,T,C	245;246;240,1,1	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5804	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3605	200.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2318	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2321	124.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	792	792	C	177	C	177	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	560	284	porB1a	984	226	90.71	porB1a.l6.c17.ctg.2	591	32.4	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	29;31;31	T;T;A	29;31;31	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	560	284	porB1a	984	226	90.71	porB1a.l6.c17.ctg.2	591	32.4	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	63;63;63	C;A;T	63;63;63	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	560	284	porB1a	984	226	90.71	porB1a.l6.c17.ctg.2	591	32.4	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	63;63;63	A;G;T	63;63;63	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	560	284	porB1a	984	226	90.71	porB1a.l6.c17.ctg.2	591	32.4	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	63;63;63	T;A,C;C	63;62,1;63	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	560	284	porB1a	984	226	90.71	porB1a.l6.c17.ctg.2	591	32.4	0	.	p	.	0	R307E	NONSYN	919	921	AGA	161	163	GAA	1;1;1	G;A;A	1;1;1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	560	284	porB1a	984	226	90.71	porB1a.l6.c17.ctg.2	591	32.4	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	560	284	porB1a	984	226	90.71	porB1a.l6.c17.ctg.2	591	32.4	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	2;2;2	A;T;C	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	560	284	porB1a	984	226	90.71	porB1a.l6.c17.ctg.2	591	32.4	0	.	p	.	0	A316S	NONSYN	946	948	GCG	188	190	TCG	2;2;2	T;C;G	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	560	284	porB1a	984	226	90.71	porB1a.l6.c17.ctg.2	591	32.4	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	560	284	porB1a	984	226	90.71	porB1a.l6.c17.ctg.2	591	32.4	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	2;2;2	A;G;C	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	560	284	porB1a	984	226	90.71	porB1a.l6.c17.ctg.2	591	32.4	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	2;2;3	G;C;C	2;2;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	560	284	porB1a	984	226	90.71	porB1a.l6.c17.ctg.2	591	32.4	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	3;3;3	G;T;T	3;3;3	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3030	porB1b	1035	1035	98.85	porB1b.l6.c17.ctg.1	2040	184.5	0	.	p	.	0	R143G	NONSYN	427	429	AGA	1000	1002	GGA	275;276;276	G;G;A,G,C	275;276;274,1,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3030	porB1b	1035	1035	98.85	porB1b.l6.c17.ctg.1	2040	184.5	0	.	p	.	0	.	INDELS	629	630	AA	1203	1205	TAG	267;264;262	T;A,C;G	267;263,1;262	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3030	porB1b	1035	1035	98.85	porB1b.l6.c17.ctg.1	2040	184.5	0	.	p	.	0	.	MULTIPLE	631	633	TAC	1207	1210	CAAT	262;266;265;265	C,A;A;A;T,A	261,1;266;265;264,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3030	porB1b	1035	1035	98.85	porB1b.l6.c17.ctg.1	2040	184.5	0	.	p	.	0	N212fs	FSHIFT	634	634	A	1212	1212	T	266	T,G	265,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3030	porB1b	1035	1035	98.85	porB1b.l6.c17.ctg.1	2040	184.5	1	SNP	p	G120K	0	.	.	358	360	GGT	931	933	GGT	251;251;253	G,T;G;T	250,1;251;253	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3030	porB1b	1035	1035	98.85	porB1b.l6.c17.ctg.1	2040	184.5	1	SNP	p	A121D	0	.	.	361	363	GCC	934	936	GCC	251;253;252	G;C;C	251;253;252	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3030	porB1b	1035	1035	98.85	porB1b.l6.c17.ctg.1	2040	184.5	1	SNP	p	A121N	0	.	.	361	363	GCC	934	936	GCC	251;253;252	G;C;C	251;253;252	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	10624	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5373	246.3	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2283	2285	CAT	264;261;258	C,G,A;A,G;T,G	261,1,1;260,1;257,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	1490	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1546	120.2	1	SNP	p	V57M	0	.	.	169	171	GTG	739	741	GTG	269;270;272	G;T,G;G	269;269,1;272	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
